LENZ Therapeutics, Inc. (LENZ)
5.83
+0.03
(+0.52%)
USD |
NASDAQ |
Sep 03, 16:00
5.835
0.00 (0.00%)
After-Hours: 20:00
LENZ Therapeutics Research and Development Expense (TTM) : 3.791M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.791M |
| March 31, 2026 | 12.85M |
| December 31, 2025 | 18.67M |
| September 30, 2025 | 24.54M |
| June 30, 2025 | 27.20M |
| March 31, 2025 | 25.08M |
| December 31, 2024 | 29.80M |
| September 30, 2024 | 43.47M |
| June 30, 2024 | 54.02M |
| March 31, 2024 | 59.72M |
| December 31, 2023 | 59.50M |
| September 30, 2023 | 56.21M |
| Date | Value |
|---|---|
| June 30, 2023 | 55.34M |
| March 31, 2023 | 60.48M |
| December 31, 2022 | 68.40M |
| September 30, 2022 | 63.36M |
| June 30, 2022 | 55.91M |
| March 31, 2022 | 50.80M |
| December 31, 2021 | 37.93M |
| September 30, 2021 | 33.12M |
| June 30, 2021 | 26.74M |
| March 31, 2021 | 14.50M |
| December 31, 2020 | 9.123M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Ocular Therapeutix, Inc. | 223.51M |
| Enveric Biosciences, Inc. | 2.476M |
| Liquidia Corp. | 54.95M |
| Aquestive Therapeutics, Inc. | 15.89M |
| Impact BioMedical, Inc. | 0.284M |